In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics (TGTX – Research ...

TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the ...

TG Therapeutics (TGTX) announced the presentation of data highlighting BRIUMVI in patients with relapsing forms of multiple sclerosis, at the ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis ...

Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional ...

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the ...

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Following a setback in June 2022, when the US regulator extended the Prescription Drug User Fee Act (PDUFA) goal date, the US FDA approved TG Therapeutics’ Briumvi (ublituximab-xiiy), for the ...

TG Therapeutics's revenues have an average growth rate of 333.9% with operating expenses growing at -6.5%. The company's ...